StreetAlpha.app
Home › Stocks › ABCL

AbCellera Biologics Inc. (ABCL)

Healthcare
$9.69
▼ −7.45%
LAST CLOSE · NOV 20

AbCellera discovers antibodies and develops them with pharmaceutical, biotechnology and nonprofit partners. It last closed at $9.69 on Nov 20, down 7.45% on the day. The next earnings report for ABCL is expected around Tue, Feb 23, 2027, after the close. For the quarter ended Sep 2026, ABCL reported EPS of -$0.13 on revenue of $10.6M, with revenue up 18.8% from a year ago. Over its last 8 reports the stock moved an average of 5.5% the session after earnings. Over the last 12 months ABCL insiders bought $3.5M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ABCL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ABCL.

Key Stats

Last 12 months
Results
Revenue
$67.9M
+92.1% vs a year ago
Net income
−$148.3M
−218.6% margin
EPS (diluted)
−$0.48
Free cash flow
−$32.9M
−48.4% margin
Valuation
Market cap
$3.2B
326.6M shares
P/E
–
No P/E while losing money
Price to sales
46.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$163.8M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
326.6M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $375.2M$375.2MFY2021FY2022: $485.4M$485.4MFY2022FY2023: $38.0M$38.0MFY2023FY2024: $28.8M$28.8MFY2024FY2025: $75.1M$75.1MFY2025

From ABCL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Feb 23
Estimated date · After the close
Reported EPS
-$0.13
Quarter ended Sep 2026
Year ago EPS
-$0.19
Same quarter last year
Revenue
$10.6M
+18.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.11Dec '24Mar 2025: -$0.15Mar '25Jun 2025: -$0.12Jun '25Sep 2025: -$0.19Sep '25Dec 2025: -$0.03Dec '25Mar 2026: -$0.14Mar '26Jun 2026: -$0.18Jun '26Sep 2026: -$0.13Sep '26Latest -$0.13
Revenue by quarter
Dec 2024: $5.0MDec '24Mar 2025: $4.2MMar '25Jun 2025: $17.1MJun '25Sep 2025: $9.0MSep '25Dec 2025: $44.9MDec '25Mar 2026: $8.3MMar '26Jun 2026: $4.0MJun '26Sep 2026: $10.6MSep '26Latest $10.6M
How ABCL moved after its last 8 reports
Average move the session after a report ±5.5%
Nov 9, 2026After the close−0.3%
Aug 5, 2026After the close+10.3%
May 11, 2026After the close−5.7%
Feb 24, 2026After the close−0.9%
Nov 6, 2025After the close−13.7%
Aug 7, 2025After the close+0.2%
May 8, 2025After the close+1.0%
Feb 27, 2025After the close−11.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ABCLStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on ABCL: 0 upgrades, 0 downgrades, 1 initiation
Lake Street CapitalInitiated
Nov 21  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on ABCL
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ABCL

Technical Analysis

ABCL · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend, nearing oversold

The stock is 22% below its 20 day and 27% below its 50 day average. It is 23% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot S1 at $9.43, and the nearest resistance the Pivot at $9.84.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityNormal, 9.0%/day
Key levels
$15.0252 week high+55.0%
$12.3050 day average+26.9%
$11.82Swing high (Sep 3)+22.0%
$11.7920 day average+21.7%
$10.49100 day average+8.3%
$10.11Pivot R1+4.3%
$9.84Pivot+1.5%
$9.69Last close
$9.43Pivot S1−2.7%
$7.42200 day average−23.4%
$5.02Swing low (Jun 9)−48.2%
$2.7552 week low−71.6%
Indicators
RSI (14)33.92Weak, oversold below 30Neutral
MACD-0.47Below its signal lineBearish
Stochastic6.3Near the bottom of its rangeOversold
ADX (14)14.8No clear trend
Williams %R-96.8Oversold below −80, overbought above −20Oversold
CCI (20)-200.0Oversold below −100, overbought above 100Oversold
Rate of change−18.4%Change over 10 sessionsBearish
ATR (14)$0.87Typical daily range, 9.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for ABCL

What happened before

See how ABCL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ABCL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ABCL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ABCLHow many large options trades hit ABCL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ABCL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●91 buying vs 87 selling
  • ▲Held by funds +5.0 pts
  • ▲Funds holding +12
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding165153+7.8%
In funds' top 1021+100.0%
Held by funds40.6%35.5%+5.0 pts
New / increased44 / 4739 / 35+23.0%
Reduced / sold out54 / 3354 / 26+8.8%
Put/call ratio3.264.62−29.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ABCL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ABCL Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$3.5M11 buys · 4 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $796K between Nov 12 and Nov 13.
2026-02 bought $857K2026-05 bought $95K2026-08 bought $1.5M2026-11 bought $796KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 13Andrew BoothCFOBuy8,600$11.33$97K
Nov 12Thermopylae Holdings Ltd.10% ownerBuy60,565$11.54$699K
Aug 24Michael R HaydenDirectorBuy53,613$10.64$570K
Aug 18John S. MontalbanoDirectorBuy10,000$11.03$110K
Aug 14Andrew BoothCFOBuy37,200$10.32$384K
Aug 12Michael R HaydenDirectorBuy46,387$10.37$481K
Every insider buy and sale for ABCL over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ABCL insider trades →

From SEC Form 4 filings by ABCL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABCL is in one of them and how their past ABCL trades turned out.

ABCL in the AI portfolios
Loading…

ABCL News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ABCL in an article yet. Here's the latest on the wider market.

ABCL in the news

About AbCellera Biologics

AbCellera is a biotechnology company based in Vancouver, British Columbia, Canada. It uses its antibody discovery and development platform to find antibodies that partners can turn into drug candidates. Its partners include pharmaceutical companies, biotechnology companies, and nonprofit and government organizations. AbCellera receives upfront payments for technology access and discovery research, and it may also receive milestone payments and royalties if partner drugs advance or sell.

Headquarters
Vancouver, British Columbia, Canada